Also trades as: 0IL8.L (LSE) · $vol 0M
KYNB NASDAQ
Kyntra Bio, Inc.
1W: -9.1%
1M: -26.0%
3M: -13.0%
YTD: -31.1%
$6.31
-0.19 (-2.92%)
Weekly Expected Move ±4.5%
$6
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-06-17
Earliest Filing
2025-09-05
Latest Filing
partner: 4
acquirer: 2
licensee: 2
Counterparties (Filed by KYNB)
8 relationshipsCompanies named in KYNB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AstraZeneca Treasury Limited | AZN | acquirer | Acquired FibroGen International (Hong Kong) Ltd. for approximately $220 million | 2025-09-05 | View |
| Fortis Therapeutics, Inc. | — | partner | Amendment to Evaluation Agreement and Option Agreement and Plan of Merger | 2025-03-28 | View |
| AstraZeneca Treasury Limited | AZN | acquirer | Acquired FibroGen International (Hong Kong) Ltd. for approximately $160 million | 2025-02-20 | View |
| Astellas Pharma Inc. | — | partner | Holds commercialization license for roxadustat in Europe, Japan, CIS, Middle East, and South Africa | 2025-02-20 | View |
| Beijing Falikang Pharmaceutical Co., Ltd. | — | partner | Joint venture partner in the roxadustat distribution business in China | 2025-02-20 | View |
| Eluminex Biosciences (Suzhou) Limited | — | licensee | Exclusively licensed global rights for FibroGen's biosynthetic cornea technology | 2021-07-20 | View |
| FibroGen, Inc. | FGEN | licensee | Granted exclusive global license rights for its biosynthetic cornea technology | 2021-07-20 | View |
| HiFiBiO Therapeutics | — | partner | Exclusive license and option agreement for Galectin-9, CXCR5, and CCR8 programs with upfront payment and milestone payme | 2021-06-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Officer/Director Change | View | |
| 2026-08-31 | Material Agreement; Financial Obligation; Regulation FD; Exhibits | Agreement | View |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-06-09 | Other Events | View | |
| 2026-04-09 | Delisting Notice | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-07 | Amendments to Articles of Incorporation or Bylaws; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Other Events | View | |
| 2025-09-05 | Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits | Acquisition | View |
| 2025-09-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-14 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-14 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-06-13 | Termination of Material Definitive Agreement | View | |
| 2025-06-12 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-06-09 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR